Mark Jit

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/793831/publications.pdf

Version: 2024-02-01

228 papers	26,273 citations	28242 55 h-index	9579 142 g-index
285 all docs	285 docs citations	285 times ranked	32658 citing authors

#	Article	IF	Citations
1	Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLoS Medicine, 2008, 5, e74.	3.9	2,355
2	Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science, 2021, 372, .	6.0	2,103
3	Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. The Lancet Global Health, 2020, 8, e488-e496.	2.9	2,067
4	Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infectious Diseases, The, 2020, 20, 553-558.	4.6	1,999
5	The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health, The, 2020, 5, e261-e270.	4.7	1,600
6	Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature Medicine, 2020, 26, 1205-1211.	15.2	1,404
7	Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet, The, 2021, 397, 1023-1034.	6.3	885
8	Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health, 2020, 8, e1003-e1017.	2.9	760
9	Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health, The, 2020, 5, e375-e385.	4.7	730
10	Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. Lancet Infectious Diseases, The, 2020, 20, 1151-1160.	4.6	710
11	Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Computational Biology, 2017, 13, e1005697.	1.5	666
12	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 575-590.	6.3	421
13	Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 781-789.	4.6	343
14	Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefitâ€“risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. The Lancet Global Health, 2020, 8, e1264-e1272.	2.9	265
15	The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Medicine, 2021, 19, 40.	2.3	257
16	Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ: British Medical Journal, 2008, 337, a769-a769.	2.4	245
17	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health, The, 2016, 1, e8-e17.	4.7	210
18	The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policy. Journal of Infection, 2014, 68, 363-371.	1.7	199

#	Article	IF	Citations
19	COVID-19 vaccine challenges: What have we learned so far and what remains to be done?. Health Policy, 2021, 125, 553-567.	1.4	199
20	Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. The Lancet Global Health, 2014, 2, e406-e414.	2.9	194
21	The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Medicine, 2016, 13, e1002181.	3.9	178
22	Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation. Vaccine, 2010, 28, 2370-2384.	1.7	160
23	Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet, The, 2016, 387, 367-375.	6.3	154
24	Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study. Lancet Public Health, The, 2021, 6, e12-e20.	4.7	153
25	Global Case-Fatality Rates in Pediatric Severe Sepsis and Septic Shock. JAMA Pediatrics, 2019, 173, 352.	3.3	152
26	Adjusting for Inflation and Currency Changes Within Health Economic Studies. Value in Health, 2019, 22, 1026-1032.	0.1	151
27	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet, The, 2021, 397, 398-408.	6.3	144
28	Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections. BMC Medicine, 2020, 18, 332.	2.3	129
29	What types of contacts are important for the spread of infections? Using contact survey data to explore European mixing patterns. Epidemics, 2011, 3, 143-151.	1.5	123
30	The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infectious Diseases, The, 2021, 21, 962-974.	4.6	117
31	Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. PLoS Computational Biology, 2021, 17, e1009098.	1.5	115
32	Social contact patterns relevant to the spread of respiratory infectious diseases in Hong Kong. Scientific Reports, 2017, 7, 7974.	1.6	107
33	Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12911-12919.	3.3	107
34	The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Medicine, 2015, 13, 209.	2.3	106
35	Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ: British Medical Journal, 2011, 343, d5775-d5775.	2.4	102
36	Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study. Lancet Infectious Diseases, The, 2021, 21, 482-492.	4.6	100

#	Article	IF	Citations
37	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics, 2016, 34, 227-244.	1.7	97
38	Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health, 2012, 12, 878.	1.2	96
39	Modelling the Epidemiology of Infectious Diseases for Decision Analysis. Pharmacoeconomics, 2011, 29, 371-386.	1.7	95
40	Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2018, 21, 1133-1149.	0.1	94
41	Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine, 2010, 28, 4091-4102.	1.7	92
42	Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine, 2013, 31, 3786-3804.	1.7	91
43	A systematic review of the social and economic burden of influenza in low- and middle-income countries. Vaccine, 2015, 33, 6537-6544.	1.7	91
44	The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine, 2009, 27, 6121-6128.	1.7	88
45	The impact of COVID-19 control measures on social contacts and transmission in Kenyan informal settlements. BMC Medicine, 2020, 18, 316.	2.3	88
46	Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infectious Diseases, The, 2019, 19, 717-727.	4.6	81
47	Within-host dynamics shape antibiotic resistance in commensal bacteria. Nature Ecology and Evolution, 2019, 3, 440-449.	3.4	76
48	Mortality in Pediatric Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Journal of Intensive Care Medicine, 2019, 34, 563-571.	1.3	76
49	The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study. PLoS ONE, 2011, 6, e17030.	1.1	75
50	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). British Journal of Cancer, 2020, 123, 510-517.	2.9	74
51	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health, The, 2017, 2, e367-e374.	4.7	72
52	Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. The Lancet Global Health, 2019, 7, e58-e67.	2.9	72
53	Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine, 2018, 36, 4806-4815.	1.7	68
54	Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. The Lancet Global Health, 2019, 7, e472-e481.	2.9	68

#	Article	IF	Citations
55	Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study. Lancet Infectious Diseases, The, 2022, 22, 657-667.	4.6	68
56	Response strategies for COVID-19 epidemics in African settings: a mathematical modelling study. BMC Medicine, 2020, 18, 324.	2.3	66
57	A cross-sectional analysis of meteorological factors and SARS-CoV-2 transmission in 409 cities across 26 countries. Nature Communications, 2021, 12, 5968.	5.8	66
58	Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy. Vaccine, 2015, 33, 1291-1296.	1.7	64
59	Determining environmental and anthropogenic factors which explain the global distribution of Aedes aegypti and Ae. albopictus. BMJ Global Health, 2018, 3, e000801.	2.0	64
60	Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance. Lancet Infectious Diseases, The, 2018, 18, e204-e213.	4.6	63
61	Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ, The, 2015, 350, g7584-g7584.	3.0	62
62	Patterns of human social contact and contact with animals in Shanghai, China. Scientific Reports, 2019, 9, 15141.	1.6	61
63	Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden. The Lancet Global Health, 2022, 10, e807-e819.	2.9	61
64	Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5Âyears in 72 Gavi-eligible countries. BMC Medicine, 2020, 18, 82.	2.3	59
65	The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. Health Affairs, 2018, 37, 316-324.	2.5	57
66	Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Medicine, 2019, 17, 180.	2.3	57
67	Impact of measles supplementary immunization activities on reaching children missed by routine programs. Vaccine, 2018, 36, 170-178.	1.7	56
68	Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC Medicine, 2021, 19, 45.	2.3	56
69	Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. ELife, 2021, 10, .	2.8	54
70	A global agenda for older adult immunization in the COVID-19 era: A roadmap for action. Vaccine, 2021, 39, 5240-5250.	1.7	52
71	Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Medicine, 2020, 18, 38.	2.3	52
72	7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?. PLoS ONE, 2011, 6, e26190.	1.1	52

#	Article	IF	Citations
73	Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: A survey of mothers and adolescents. Vaccine, 2013, 32, 78-84.	1.7	51
74	Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. Vaccine, 2015, 33, 3788-3794.	1.7	51
75	Influenza vaccines in low and middle income countries. Human Vaccines and Immunotherapeutics, 2013, 9, 1500-1511.	1.4	50
76	Mortality, neurodevelopmental impairments, and economic outcomes after invasive group B streptococcal disease in early infancy in Denmark and the Netherlands: a national matched cohort study. The Lancet Child and Adolescent Health, 2021, 5, 398-407.	2.7	50
77	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 2021, 10, .	2.8	50
78	Burden of Severe Pneumonia, Pneumococcal Pneumonia and Pneumonia Deaths in Indian States: Modelling Based Estimates. PLoS ONE, 2015, 10, e0129191.	1.1	50
79	Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. Vaccine, 2014, 32, 5845-5853.	1.7	49
80	Reassessing the value of vaccines. The Lancet Global Health, 2014, 2, e251-e252.	2.9	49
81	An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations. Frontiers in Public Health, 2021, 9, 722927.	1.3	49
82	The economic burden of influenza-associated outpatient visits and hospitalizations in China: a retrospective survey. Infectious Diseases of Poverty, 2015, 4, 44.	1.5	48
83	Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clinical Infectious Diseases, 2017, 64, ciw845.	2.9	46
84	Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. The Lancet Global Health, 2019, 7, e1541-e1552.	2.9	46
85	The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine, 2010, 29, 115-122.	1.7	44
86	Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance: TableÂ1. Sexually Transmitted Infections, 2015, 91, 284-286.	0.8	42
87	Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: A systematic review and meta-analysis. Vaccine, 2013, 31, 5168-5177.	1.7	41
88	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100184.	4.5	41
89	Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis. Value in Health, 2020, 23, 1580-1591.	0.1	41
90	Guidelines for multi-model comparisons of the impact of infectious disease interventions. BMC Medicine, 2019, 17, 163.	2.3	39

#	Article	IF	Citations
91	Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. The Lancet Global Health, 2020, 8, e536-e544.	2.9	39
92	Incidence and disease burden of herpes zoster in the population aged â‰¥50 years in China: Data from an integrated health care network. Journal of Infection, 2021, 82, 253-260.	1.7	38
93	Mathematical modelling for antibiotic resistance control policy: do we know enough?. BMC Infectious Diseases, 2019, 19, 1011.	1.3	37
94	Systematic review of model-based cervical screening evaluations. BMC Cancer, 2015, 15, 334.	1.1	36
95	Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Human Vaccines and Immunotherapeutics, 2013, 9, 834-840.	1.4	35
96	Seasonal influenza vaccination delivery through community pharmacists in England: evaluation of the London pilot. BMJ Open, 2016, 6, e009739.	0.8	34
97	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infectious Diseases, The, 2021, 21, 1598-1610.	4.6	34
98	Estimating number of cases and spread of coronavirus disease (COVID-19) using critical care admissions, United Kingdom, February to March 2020. Eurosurveillance, 2020, 25, .	3.9	34
99	Household Catastrophic Healthcare Expenditure and Impoverishment Due to Rotavirus Gastroenteritis Requiring Hospitalization in Malaysia. PLoS ONE, 2015, 10, e0125878.	1.1	33
100	COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness. PLoS Medicine, 2021, 18, e1003815.	3.9	33
101	Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?. Applied Health Economics and Health Policy, 2016, 14, 245-252.	1.0	32
102	Determinants of methicillin-resistant Staphylococcus aureus (MRSA) prevalence in the Asia-Pacific region: A systematic review and meta-analysis. Journal of Global Antimicrobial Resistance, 2019, 16, 17-27.	0.9	32
103	Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls. Clinical Infectious Diseases, 2022, 75, e962-e973.	2.9	32
104	Cost of Treatment and QALYs Lost Due to Genital Warts: Data for the Economic Evaluation of HPV Vaccines in the United Kingdom. Sexually Transmitted Diseases, 2009, 36, 515-521.	0.8	31
105	Evaluating the potential risks and benefits of infant rotavirus vaccination in England. Vaccine, 2014, 32, 3604-3610.	1.7	31
106	Estimating the opportunity costs of bedâ€days. Health Economics (United Kingdom), 2018, 27, 592-605.	0.8	31
107	Exploring surveillance data biases when estimating the reproduction number: with insights into subpopulation transmission of COVID-19 in England. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200283.	1.8	31
108	The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness â€“ A systematic review. Vaccine, 2020, 38, 460-469.	1.7	30

#	Article	IF	Citations
109	The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Eurosurveillance, 2021, 26, .	3.9	30
110	Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC Health Services Research, 2017, 17, 353.	0.9	29
111	Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients. Clinical Infectious Diseases, 2018, 67, 693-700.	2.9	28
112	The effect of travel restrictions on the geographical spread of COVID-19 between large cities in China: a modelling study. BMC Medicine, 2020, 18, 259.	2.3	28
113	Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, 2015, 33, A240-A247.	1.7	27
114	Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization. Vaccine, 2015, 33, A233-A239.	1.7	27
115	Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. Lancet Regional Health - Europe, The, 2021, 9, 100221.	3.0	26
116	Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks. BMC Medicine, 2018, 16, 139.	2.3	24
117	Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60Âyears and above in mainland China: a modelling analysis. BMC Medicine, 2020, 18, 90.	2.3	24
118	Estimating the impact of reopening schools on the reproduction number of SARS-CoV-2 in England, using weekly contact survey data. BMC Medicine, 2021, 19, 233.	2.3	24
119	Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region: a mathematical modelling study. Lancet Regional Health - Europe, The, 2022, 12, 100267.	3.0	24
120	Quantifying the public's view on social value judgments in vaccine decision-making: A discrete choice experiment. Social Science and Medicine, 2019, 228, 181-193.	1.8	23
121	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value in Health, 2021, 24, 1828-1834.	0.1	22
122	Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?. Vaccine, 2014, 32, 3237-3242.	1.7	21
123	Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. Vaccine, 2017, 35, 3922-3929.	1.7	21
124	Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. Value in Health, 2018, 21, 1250-1258.	0.1	21
125	The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making. SSRN Electronic Journal, 0, , .	0.4	21
126	Comparison of Public Responses to Containment Measures During the Initial Outbreak and Resurgence of COVID-19 in China: Infodemiology Study. Journal of Medical Internet Research, 2021, 23, e26518.	2.1	21

#	Article	IF	Citations
127	Stark choices: exploring health sector costs of policy responses to COVID-19 in low-income and middle-income countries. BMJ Global Health, 2021, 6, e005759.	2.0	21
128	Systematic review of economic evaluations of vaccination programs in mainland China: Are they sufficient to inform decision making?. Vaccine, 2015, 33, 6164-6172.	1.7	20
129	Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review. BMC Medicine, 2021, 19, 318.	2.3	20
130	Stakeholdersâ€™ perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study. BMC Public Health, 2015, 15, 356.	1.2	19
131	Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	19
132	A bibliometric analysis of systematic reviews on vaccines and immunisation. Vaccine, 2018, 36, 2254-2261.	1.7	18
133	Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Medicine, 2021, 19, 62.	2.3	18
134	Targeted vaccination in healthy school children â€“ Can primary school vaccination alone control influenza?. Vaccine, 2015, 33, 5415-5424.	1.7	17
135	Clustering of contacts relevant to the spread of infectious disease. Epidemics, 2016, 17, 1-9.	1.5	17
136	Assessing dengue vaccination impact: Model challenges and future directions. Vaccine, 2016, 34, 4461-4465.	1.7	17
137	The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy. Vaccine, 2016, 34, 5562-5570.	1.7	17
138	Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine, 2017, 35, 1055-1063.	1.7	17
139	The need for sustainability and alignment of future support for National Immunization Technical Advisory Groups (NITAGs) in low and middle-income countries. Human Vaccines and Immunotherapeutics, 2018, 14, 1539-1541.	1.4	17
140	Caregiver and service provider vaccine confidence following the Changchun Changsheng vaccine incident in China: A cross-sectional mixed methods study. Vaccine, 2020, 38, 6882-6888.	1.7	17
141	Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. Vaccine, 2020, 38, 6075-6077.	1.7	17
142	Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018. Value in Health, 2021, 24, 61-66.	0.1	17
143	Association of enteropathogen detection with diarrhoea by age and high versus low child mortality settings: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e1402-e1410.	2.9	17
144	Travel measures in the SARS-CoV-2 variant era need clear objectives. Lancet, The, 2022, 399, 1367-1369.	6.3	17

#	Article	IF	Citations
145	Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. International Journal of Gynecological Cancer, 2019, 29, 669-675.	1.2	16
146	Meeting Report: WHO Workshop on modelling global mortality and aetiology estimates of enteric pathogens in children under five. Cape Town, 28â€“29th November 2018. Vaccine, 2020, 38, 4792-4800.	1.7	16
147	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. Health Technology Assessment, 2020, 24, 1-86.	1.3	16
148	World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens. Vaccine, 2021, 39, 7521-7525.	1.7	16
149	The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study. The Lancet Regional Health - Western Pacific, 2022, 21, 100389.	1.3	16
150	Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries. Health Affairs, 2016, 35, 227-234.	2.5	15
151	Potential lives saved in 73 countries by adopting multiâ€cohort vaccination of 9â€“14â€yearâ€old girls against human papillomavirus. International Journal of Cancer, 2018, 143, 317-323.	2.3	15
152	Divergent vaccination policies could fuel mistrust and hesitancy. Lancet, The, 2021, 397, 2333.	6.3	15
153	Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children. Journal of Infectious Diseases, 2022, 226, S95-S101.	1.9	15
154	Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. Lancet Regional Health - Europe, The, 2022, 17, 100381.	3.0	15
155	Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 425-435.	0.7	14
156	Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. Health Policy and Planning, 2018, 33, 204-214.	1.0	14
157	Estimating burden of influenzaâ€associated influenzaâ€like illness and severe acute respiratory infection at public healthcare facilities in Romania during the 2011/12â€2015/16 influenza seasons. Influenza and Other Respiratory Viruses, 2018, 12, 183-192.	1.5	14
158	Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis. BMC Medicine, 2018, 16, 127.	2.3	14
159	Systematic Review on the Acute Cost-of-illness of Sepsis and Meningitis in Neonates and Infants. Pediatric Infectious Disease Journal, 2020, 39, 35-40.	1.1	14
160	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ Global Health, 2020, 5, e003006.	2.0	14
161	Quantifying Parameter and Structural Uncertainty of Dynamic Disease Transmission Models Using MCMC. Medical Decision Making, 2015, 35, 633-647.	1.2	13
162	Modeling the impact of rubella vaccination in Vietnam. Human Vaccines and Immunotherapeutics, 2016, 12, 150-158.	1.4	13

#	Article	IF	Citations
163	Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework. Pharmacoeconomics, 2018, 36, 79-90.	1.7	13
164	Exploring equity in health and poverty impacts of control measures for SARS-CoV-2 in six countries. BMJ Global Health, 2021, 6, e005521.	2.0	13
165	A global assessment of the impact of school closure in reducing COVID-19 spread. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, 20210124.	1.6	13
166	The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models. Vaccine, 2020, 38, 5139-5147.	1.7	12
167	From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness. Preventive Medicine, 2021, 144, 106354.	1.6	12
168	Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200266.	1.8	12
169	Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection. Vaccine, 2021, 39, 4391-4398.	1.7	12
170	WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. BMC Medicine, 2022, 20, 88.	2.3	12
171	Predicting the lifeâ€time benefit of schoolâ€based smoking prevention programmes. Addiction, 2010, 105, 1109-1116.	1.7	11
172	Understanding differences in cervical cancer incidence in Western Europe: comparing Portugal and England. European Journal of Public Health, 2018, 28, 343-347.	0.1	11
173	The global impact and cost-effectiveness of a melioidosis vaccine. BMC Medicine, 2019, 17, 129.	2.3	11
174	A Scoping Review of Investment Cases for Vaccines and Immunization Programs. Value in Health, 2019, 22, 942-952.	0.1	11
175	Comparative Distributional Impact of Routine Immunization and Supplementary Immunization Activities in Delivery of Measles Vaccine in Low- and Middle-Income Countries. Value in Health, 2020, 23, 891-897.	0.1	11
176	The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study. International Journal for Equity in Health, 2020, 19, 10.	1.5	11
177	Quantifying the Acute Care Costs of Neonatal Bacterial Sepsis and Meningitis in Mozambique and South Africa. Clinical Infectious Diseases, 2022, 74, S64-S69.	2.9	11
178	Rapid COVID-19 vaccine rollout: immense success but challenges ahead. Lancet Infectious Diseases, The, 2022, 22, 302-304.	4.6	11
179	How can the public health impact of vaccination be estimated?. BMC Public Health, 2021, 21, 2049.	1.2	11
180	MCDA from a health economics perspective: opportunities and pitfalls of extending economic evaluation to incorporate broader outcomes. Cost Effectiveness and Resource Allocation, 2018, 16, 45.	0.6	10

#	Article	IF	Citations
181	Strengthening national vaccine decision-making: Assessing the impact of SIVAC Initiative support on national immunisation technical advisory group (NITAG) functionality in 77 low and middle-income countries. Vaccine, 2019, 37, 430-434.	1.7	9
182	A review of the costs of delivering maternal immunisation during pregnancy. Vaccine, 2020, 38, 6199-6204.	1.7	9
183	The CAPACITI Decision-Support Tool for National Immunization Programs. Value in Health, 2021, 24, 1150-1157.	0.1	9
184	Modeling the effect of vaccination on selection for antibiotic resistance in Streptococcus pneumonia e. Science Translational Medicine, 2021, 13, .	5.8	9
185	Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries. BMC Medicine, 2021, 19, 281.	2.3	9
186	Regional-based within-year seasonal variations in influenza-related health outcomes across mainland China: a systematic review and spatio-temporal analysis. BMC Medicine, 2022, 20, 58.	2.3	9
187	SARS-CoV-2 infection risk during delivery of childhood vaccination campaigns: a modelling study. BMC Medicine, 2021, 19, 198.	2.3	8
188	Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Sexually Transmitted Infections, 2019, 95, 28-35.	0.8	7
189	Effect of Pediatric Influenza Vaccination on Antibiotic Resistance, England and Wales. Emerging Infectious Diseases, 2020, 26, 138-142.	2.0	7
190	Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide. Clinical Infectious Diseases, 2022, 74, S1-S4.	2.9	7
191	Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities. Vaccine, 2021, 39, 5490-5498.	1.7	7
192	In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2022, 226, 1127-1139.	1.9	7
193	Optimizing Benefits of Testing Key Workers for Infection with SARS-CoV-2: A Mathematical Modeling Analysis. Clinical Infectious Diseases, 2020, 71, 3196-3203.	2.9	6
194	Quantifying long-term health and economic outcomes for survivors of group B Streptococcus invasive disease in infancy: protocol of a multi-country study in Argentina, India, Kenya, Mozambique and South Africa. Gates Open Research, 2020, 4, 138.	2.0	6
195	Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study. BMJ Global Health, 2021, 6, e006940.	2.0	6
196	COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery. Vaccine, 2022, 40, 4142-4149.	1.7	6
197	Fewer than three doses of HPV vaccine. Lancet Oncology, The, 2015, 16, e423-e424.	5.1	5
198	Characterizing measles transmission in India: a dynamic modeling study using verbal autopsy data. BMC Medicine, 2017, 15, 151.	2.3	5

#	Article	IF	Citations
199	Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine, 2021, 39, 871-875.	1.7	5
200	Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine, 2021, 39, 2255-2263.	1.7	5
201	Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam. International Journal of Infectious Diseases, 2021, 112, 136-143.	1.5	5
202	Nosocomial Transmission of C. difficile in English Hospitals from Patients with Symptomatic Infection. PLoS ONE, 2014, 9, e99860.	1.1	4
203	The economic burden of dengue: no longer invisible or unavoidable. Lancet Infectious Diseases, The, 2016, 16, 873-874.	4.6	4
204	Rotavirus vaccines contribute towards universal health coverage in a mixed publicâ€“private healthcare system. Tropical Medicine and International Health, 2016, 21, 1458-1467.	1.0	4
205	Mini-review: Can non-human leucocyte antigen genes determine susceptibility to severe dengue syndromes?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 384-392.	0.7	4
206	The impact of childhood pneumococcal conjugate vaccine immunisation on all-cause pneumonia admissions in Hong Kong: A 14-year population-based interrupted time series analysis. Vaccine, 2021, 39, 2628-2635.	1.7	4
207	Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis. Vaccine, 2021, 39, 4500-4509.	1.7	4
208	Integrating economic and health evidence to inform Covid-19 policy in low- and middle- income countries. Wellcome Open Research, 0, 5, 272.	0.9	4
209	Differential health impact of intervention programs for time-varying disease risk: a measles vaccination modeling study. BMC Medicine, 2022, 20, 113.	2.3	4
210	Now or later: Health impacts of delaying singleâ€dose <scp>HPV</scp> vaccine implementation in a highâ€burden setting. International Journal of Cancer, 2022, 151, 1804-1809.	2.3	4
211	The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model. BMC Public Health, 2022, 22, 1003.	1.2	4
212	Building a new communication paradigm: Can we influence influenza perception?. Vaccine, 2015, 33, 7044-7046.	1.7	3
213	Adding interventions to mass measles vaccinations in India. Bulletin of the World Health Organization, 2016, 94, 718-727.	1.5	3
214	Mapping the cryptic spread of the 2015â€“2016 global Zika virus epidemic. BMC Medicine, 2020, 18, 399.	2.3	3
215	Shaping meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness. Vaccine, 2020, 38, 3179-3183.	1.7	3
216	Estimation of country-level incidence of early-onset invasive Group B Streptococcus disease in infants using Bayesian methods. PLoS Computational Biology, 2021, 17, e1009001.	1.5	3

#	Article	IF	Citations
217	Prevalence and Determinants of Vaginal Infection With Human Papillomavirus Among Female University Students in Vietnam. In Vivo, 2022, 36, 241-250.	0.6	3
218	The role of vaccines in combating antimicrobial resistance. , 2020, , 181-206.		2
219	HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. Sexually Transmitted Infections, 2021, 97, 382-386.	0.8	2
220	How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations. Value in Health, 2021, 24, 1391-1399.	0.1	1
221	High-dose influenza vaccines make economic sense for older people. Lancet Infectious Diseases, The, 2015, 15, 1372-1373.	4.6	0
222	The role of pneumococcal conjugate vaccination in reducing pneumonia mortality. The Lancet Global Health, 2019, 7, e173-e174.	2.9	0
223	O06.4â€…Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac). , 2019, , .		0
224	Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020. Wellcome Open Research, 2021, 6, 255.	0.9	0
225	Enzymes provide demographers with food for thought. ELife, 2012, 1, e00340.	2.8	0
226	Designing a multi-layered surveillance approach to detecting SARS-CoV-2: A modelling study. Wellcome Open Research, 0, 5, 218.	0.9	0
227	Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020. Wellcome Open Research, 0, 6, 255.	0.9	0
228	Transmission dynamics of SARS-CoV-2 in a strictly-Orthodox Jewish community in the UK. Scientific Reports, 2022, 12, .	1.6	0